Page last updated: 2024-09-04

schizandrer a and Disease Models, Animal

schizandrer a has been researched along with Disease Models, Animal in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ding, G; Guo, W; Liu, F; Lu, H; Zhan, Y; Zhang, M; Zheng, N1
Li, B; Li, D; Ma, F; Meng, X; Shi, L; Sun, X; Tian, J; Wang, Y1
Chang, R; Dou, L; Li, X; Li, Y; Wang, Y; Yang, X; Yue, Y; Zhang, W1
Bi, K; Guo, L; Jia, Y; Li, H; Li, X; Liu, Z; Mao, X; Xu, X; Zhao, X1
Chen, X; He, Y; Peng, D; Shen, Y; Zhang, Q; Zhou, F1
Ci, X; Jie, J; Li, D; Li, Y; Liu, C; Peng, L; Wen, Z1
Chen, T; Lee, SM; Li, C; Li, Y; Yi, X; Zheng, Y1

Other Studies

7 other study(ies) available for schizandrer a and Disease Models, Animal

ArticleYear
Schisantherin A protects against liver ischemia-reperfusion injury via inhibition of mitogen-activated protein kinase pathway.
    International immunopharmacology, 2017, Volume: 47

    Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Cyclooctanes; Dioxoles; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Lignans; Liver; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Reperfusion Injury; Schisandraceae; Signal Transduction

2017
Schisantherin A alleviated alcohol-induced liver injury by the regulation of alcohol metabolism and NF-kB pathway.
    Experimental animals, 2018, Nov-01, Volume: 67, Issue:4

    Topics: Alanine Transaminase; Alcohol Dehydrogenase; Aldehyde Oxidoreductases; Animals; Aspartate Aminotransferases; Cyclooctanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2E1; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Lignans; Liver; Liver Diseases, Alcoholic; Male; Mice, Inbred C57BL; NF-kappa B; Oxidative Stress; Phytotherapy; Schisandra; Signal Transduction

2018
Protective role of deoxyschizandrin and schisantherin A against myocardial ischemia-reperfusion injury in rats.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Animals; Apoptosis; Arrhythmias, Cardiac; Cardiotonic Agents; Caspase 3; Cyclooctanes; Cytoprotection; Dioxoles; Disease Models, Animal; Gene Expression Regulation; Hemodynamics; Hydrogen Peroxide; Lignans; Male; Malondialdehyde; Membrane Glycoproteins; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; NADPH Oxidase 2; NADPH Oxidases; Polycyclic Compounds; Rats; Rats, Wistar; RNA, Messenger; Superoxide Dismutase

2013
Schisantherin A recovers Aβ-induced neurodegeneration with cognitive decline in mice.
    Physiology & behavior, 2014, Jun-10, Volume: 132

    Topics: Amyloid beta-Peptides; Analysis of Variance; Animals; Antioxidants; Brain; Cognition Disorders; Cyclooctanes; Dioxoles; Disease Models, Animal; Glutathione; Glutathione Peroxidase; Injections, Intraventricular; Lignans; Male; Malondialdehyde; Maze Learning; Mice; Mice, Inbred Strains; Neurodegenerative Diseases; Peptide Fragments; Superoxide Dismutase

2014
Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    Biochemical and biophysical research communications, 2014, Jul-04, Volume: 449, Issue:3

    Topics: Animals; Bone Resorption; Cell Differentiation; Cell Survival; Cyclooctanes; Dioxoles; Disease Models, Animal; Lignans; Mice; Mice, Inbred C57BL; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteolysis; RANK Ligand; Signal Transduction

2014
Alleviation of severe inflammatory responses in LPS-exposed mice by Schisantherin A.
    Respiratory physiology & neurobiology, 2014, Oct-01, Volume: 202

    Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Cell Movement; Cyclooctanes; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Lignans; Lipopolysaccharides; Male; Malondialdehyde; Mice; Mice, Inbred BALB C; Neutrophil Infiltration; Neutrophils; Peroxidase; Pulmonary Edema; Signal Transduction; Superoxide Dismutase; Survival Analysis

2014
Oral Delivery of a Nanocrystal Formulation of Schisantherin A with Improved Bioavailability and Brain Delivery for the Treatment of Parkinson's Disease.
    Molecular pharmaceutics, 2016, 11-07, Volume: 13, Issue:11

    Topics: Administration, Oral; Animals; Brain; Cyclooctanes; Dioxoles; Disease Models, Animal; Drug Compounding; Lignans; Male; Nanoparticles; Parkinson Disease; Rats, Sprague-Dawley; Zebrafish

2016